Interaction of FGF9 with FGFR3-IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma
Open Access
- 1 September 2020
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 40 (9), 2279-2290
- https://doi.org/10.1111/liv.14505
Abstract
Background & Aims Recently, overexpression of the fibroblast growth factor receptor 3 (FGFR3) splice variants FGFR3-IIIb and FGFR3-IIIc was found in similar to 50% of hepatocellular carcinoma (HCC). Here, we aim to identify FGFR3-IIIb/IIIc ligands, which drive the progression of HCC. Methods FACS, MTT assay and/or growth curves served to identify the FGFR3-IIIb/IIIc ligand being most effective to induce growth of hepatoma/hepatocarcinoma cell lines, established from human HCC. The most potent FGF was characterized regarding the expression levels in epithelial and stromal cells of liver and HCC and impact on neoangiogenesis, clonogenicity and invasive growth of hepatoma/hepatocarcinoma cells. Results Among all FGFR3-IIIb/IIIc ligands tested, FGF9 was the most potent growth factor for hepatoma/hepatocarcinoma cells. Replication and/or sprouting of blood/lymphendothelial cells was stimulated as well. FGF9 occurred mainly in stromal cells of unaltered liver but in epithelial cells of HCC. Every fifth HCC exhibited overexpressed FGF9 and frequent co-upregulation of FGFR3-IIIb/IIIc. In hepatoma/hepatocarcinoma cells FGF9 enhanced the capability for clonogenicity and disintegration of the blood and lymphatic endothelium, being most pronounced in cells overexpressing FGFR3-IIIb or FGFR3-IIIc, respectively. Any of the FGF9 effects in hepatoma/hepatocarcinoma cells was blocked completely by applying the FGFR1-3-specific tyrosine kinase inhibitor BGJ398 or siFGFR3, while siFGFR1/2/4 were mostly ineffective. Conclusions FGF9 acts via FGFR3-IIIb/IIIc to enhance growth and aggressiveness of HCC cells. Accordingly, blockade of the FGF9-FGFR3-IIIb/IIIc axis may be an efficient therapeutic option for HCC patients.This publication has 29 references indexed in Scilit:
- miR-26a Suppresses Tumor Growth and Metastasis by Targeting FGF9 in Gastric CancerPLOS ONE, 2013
- MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinomaHepatology, 2013
- Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine KinaseJournal of Medicinal Chemistry, 2011
- Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cellsNature Biotechnology, 2011
- Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesisHepatology, 2010
- FGF9 monomer–dimer equilibrium regulates extracellular matrix affinity and tissue diffusionNature Genetics, 2009
- New cellular tools reveal complex epithelial–mesenchymal interactions in hepatocarcinogenesisBritish Journal of Cancer, 2008
- Receptor Specificity of the Fibroblast Growth Factor FamilyJournal of Biological Chemistry, 2006
- Three-Dimensional in Vitro Angiogenesis AssaysPublished by Springer Science and Business Media LLC ,2004
- Crystal Structure of Fibroblast Growth Factor 9 Reveals Regions Implicated in Dimerization and AutoinhibitionOnline Journal of Public Health Informatics, 2001